Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis

INTRODUCTION: The purpose of this study was to evaluate clinical outcomes and drug/administration costs of treatment with tumor necrosis factor inhibitor (TNFi) agents in US veterans with rheumatoid arthritis (RA) initiating TNFi therapy. The analysis compared patients initiating and continuing a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannon, Grant W., DuVall, Scott L., Haroldsen, Candace L., Caplan, Liron, Curtis, Jeffrey R., Michaud, Kaleb, Mikuls, Ted R., Reimold, Andreas, Collier, David H., Joseph, George J., Harrison, David J., Sauer, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969320/
https://www.ncbi.nlm.nih.gov/pubmed/27352377
http://dx.doi.org/10.1007/s12325-016-0371-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969320/
https://www.ncbi.nlm.nih.gov/pubmed/27352377
http://dx.doi.org/10.1007/s12325-016-0371-0

Ejemplares similares